Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  SK Biopharmaceuticals Co., Ltd.    A326030   KR7326030004

SK BIOPHARMACEUTICALS CO., LTD.

(A326030)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
01/15/2021 01/18/2021 01/19/2021 01/20/2021 01/21/2021 Date
153000 148000 148000 148000 151500 Last
253514 419631 274255 243971 641065 Volume
-1.29% -3.27% 0.00% 0.00% +2.36% Change
Financials
Sales 2020 20,3 B 0,02 B 0,02 B
Net income 2020 -205 B -0,19 B -0,19 B
Net cash position 2020 389 B 0,35 B 0,35 B
P/E ratio 2020 -54,6x
Yield 2020 -
Sales 2021 181 B 0,16 B 0,16 B
Net income 2021 -140 B -0,13 B -0,13 B
Net cash position 2021 234 B 0,21 B 0,21 B
P/E ratio 2021 -118x
Yield 2021 -
Capitalization 11 864 B 10 785 M 10 761 M
EV / Sales 2020 584 135x
EV / Sales 2021 65 663x
Nbr of Employees -
Free-Float 21,9%
More Financials
Company
SK Biopharmaceuticals Co Ltd is a Korea-based company mainly engages in the development and manufacture of pharmaceuticals. The Company mainly develops and produces pharmaceuticals including epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, and bipolar disorder drugs, among others. The Company also engages in the new drug development business. 
Sector
Pharmaceuticals
Calendar
08/13Earnings Release
More about the company
All news about SK BIOPHARMACEUTICALS CO., LTD.
01/10South Korea's IPO market poised for record year on booming retail demand
RE
01/08South Korea's IPO market poised for record year on booming retail demand
RE
01/05SK BIOPHARMACEUTICALS : to sell Arvelle Therapeutics stake to Angelini Pharma
AQ
2020Vaccine developer SK Bioscience targets IPO in first half of 2021
RE
2020SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innova..
AQ
2020BTS manager Big Hit takes a beating as stock loses more than a fifth
RE
2020Ono Enters into License Agreement on Cenobamate, an Antiepileptic Drug with S..
AQ
2020SK Biopharmaceuticals, Ono Pharmaceutical Enter Licensing Agreement for Cenob..
AQ
2020Fans of boy band BTS join swarm of Ants chasing South Korea's hit IPO
RE
More news
News in other languages on SK BIOPHARMACEUTICALS CO., LTD.

- No features available -

More news
Chart SK BIOPHARMACEUTICALS CO., LTD.
Duration : Period :
SK Biopharmaceuticals Co., Ltd. Technical Analysis Chart | A326030 | KR7326030004 | MarketScreener
Technical analysis trends SK BIOPHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 6
Average target price 141 333,33 KRW
Last Close Price 151 500,00 KRW
Spread / Highest target 22,1%
Spread / Average Target -6,71%
Spread / Lowest Target -34,0%
EPS Revisions
Managers and Directors
NameTitle
Jeong-Woo Jo President, Chief Executive Officer & Director
Geun-Joo Hwang Non-Executive Director
Young-Ju Bang Independent Director
Hae-Young Ahn Independent Director
Min-Seop Song Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SK BIOPHARMACEUTICALS CO., LTD.-10.36%10 785
MERCK KGAA0.64%75 058
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD11.39%27 359
KYOWA KIRIN CO., LTD.0.43%14 729
BETTA PHARMACEUTICALS CO., LTD.28.34%8 355
YUHAN CORPORATION-2.53%4 163